Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Evofem Biosciences, Inc.

Market Cap 1.05M 902K 831K 779K 1.46M 98.95M 1.48M 9.82M 3.84M 48.46M 3.93M 3.85M 168M P/E Ratio 2024
-0.08x
P/E Ratio 2025 26.7x
Enterprise Value 55.46M 47.8M 44M 41.27M 77.53M 5.24B 78.3M 520M 203M 2.57B 208M 204M 8.88B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+1.27%
1 week-2.44%
Current month+14.29%
1 month+19.40%
3 months-9.09%
6 months-27.93%
Current year-15.79%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.0059
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
1.4
5 years 0
Extreme 0.0008
2,362.5
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 2017-12-31
Director of Finance/CFO 49 2023-04-12
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 2017-12-31
Director/Board Member 59 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
24-01-11Sell

Chief Financial Officer

104 0.0010%
23-12-20Sell

Director

10 0.0001%
23-04-12Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%-2.44%-13.98%-99.20% 1.05M
-0.63%-1.76%+39.80%+148.71% 1,010B
-1.94%+1.65%+52.04%+44.14% 580B
-2.39%-0.79%+15.95%+62.86% 402B
-0.46%0.00%+21.28%+19.14% 330B
-1.52%+2.45%+24.75%+33.03% 281B
-1.95%-4.32%+22.02%+12.96% 280B
-0.57%+5.00%-42.66%-48.28% 197B
-0.70%+2.19%+19.53%+54.65% 192B
-0.65%-3.26%+11.82%+56.87% 156B
Average -0.87%+0.39%+15.06%+28.49% 342.88B
Weighted average by Cap. -1.07%+1.04%+27.45%+67.14%

Financials

2024 2025
Net sales 19.36M 16.69M 15.36M 14.41M 27.07M 1.83B 27.34M 182M 70.93M 896M 72.66M 71.12M 3.1B 20.18M 17.4M 16.01M 15.02M 28.21M 1.91B 28.49M 189M 73.93M 934M 75.74M 74.14M 3.23B
Net income -8.86M -7.64M -7.03M -6.59M -12.38M -837M -12.51M -83.09M -32.46M -410M -33.25M -32.54M -1.42B 391K 337K 310K 291K 547K 36.95M 552K 3.67M 1.43M 18.1M 1.47M 1.44M 62.62M
Net Debt 45.84M 39.51M 36.36M 34.11M 64.08M 4.33B 64.72M 430M 168M 2.12B 172M 168M 7.34B 54.42M 46.9M 43.17M 40.49M 76.07M 5.14B 76.83M 510M 199M 2.52B 204M 200M 8.71B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
26-06-15 0.008000 $ +1.27% 414,999
26-06-12 0.007900 $ +9.72% 405,890
26-06-11 0.007200 $ -4.00% 34,367
26-06-10 0.007500 $ 0.00% 63,488
26-06-09 0.007500 $ -8.54% 68,079

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!